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Objective: The most common complaint from patients after subarachnoid hemorrhage (SAH) is headache. The
headache appears to be persistent and often severe. Although this problem is pervasive in the care of SAH
patients, very little data have been published to describe the nature and severity of the headache nor is there
evidence-based guidance on the appropriate treatment of headache due to SAH.
Methods: This was a retrospective medical record review of adults with aneurysmal SAH. Basic demographics,
along with pain scores and analgesic medication administration, were collected. Patients with early
vasospasm (within 7 days of ictus) were compared with patients with no vasospasm.
Results: The patient population was characteristic of the typical SAH population. Approximately 31.5% of
patients exhibited early vasospasm. These patients had higher pain scores (median 8/10) than did patients
without vasospasm (median 6/10) and required more analgesics such as acetaminophen/butalbital/caffeine.
Treatment success with any analgesic used in this population was minimal. The pain scores associated with
headache increased over the ﬁrst 7 days in both groups.
Conclusions: Headache after SAH is persistent and treatment refractory. There may be an association with
development of vasospasm and worsening of headache. Novel treatment strategies to attenuate headache in
this population are needed.
© 2014 Published by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Headache is the most common complaint of patients who present
with aneurysmal subarachnoid hemorrhage (SAH) [1]. It is thought
that the headache is primarily due to the chemical irritation of the
blood on the brain meninges, though many other factors are
associated (Fig. 1). The hypertension that tends to be present after
SAH may also contribute to the development of headache, as may the
evolution of cerebral vasospasm and hydrocephalus which may
develop as a consequence of SAH. Very little data exist regarding
the severity and treatment of headache after SAH, which likely lead to
a wide variety in practice. In fact, only one published report of
headache treatment in SAH patients is available [2].n, KY 40536-0293. Tel.: +1 859
).
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partment of Pharmacy, Fort
ess under CC BY-NC-ND license.Many of the commonly used analgesics for headache are problematic
in the acute SAH patient. Aspirin and other non-steroidal anti-
inﬂammatory drugs (NSAIDs) can inhibit platelet aggregation, thereby
exacerbatingbleeding after SAH.Opioidmedications suchasoxycodoneor
morphine can cause sedation, which may confound the neurologic exam
in these vulnerable patients. Alternative, non-opioid agents such as
tramadol also cause sedation and may reduce seizure threshold [3,4].
Combination agents such as acetaminophen/butalbital/caffeine (Fioricet)
may have various adverse effects and variable durations of action (eg.
caffeine can cause cerebral vasoconstriction, but has a short half-life;
Butalbital causes sedation and has a very prolonged half-life) [5,6]. Other
agents such as magnesium and dexamethasone have also been used for
SAH patients [2]. Magnesium may cause hypotension with rapid
administration, while dexamethasone (like all corticosteroids) is associ-
ated with a number of adverse effects (most concerning acutely are
hyperglycemia and agitation). Clinicians are often left with few evidence-
based options for treating headache, the most prevalent of which is
acetaminophen (which, in doses N4 g/daymay cause hepatic dysfunction).
The purpose of the present study was to describe the severity and
progression of early headache after SAH (within theﬁrst 7 days of ictus)
and to evaluate headache treatment patterns in our patient population.
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Fig. 1. Daily headache pain scores and TCD measurements.
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The study was a retrospective medical chart review of adult
inpatients admitted to the University of Kentucky Chandler Hospital
with aneurysmal SAH. The University Health Consortium (UHC)
database was used to identify patients with the diagnosis code for a
SAH admitted to the University of Kentucky Chandler Hospital
between July 2008 and December 2010. Patients were included if
they had an aneurysmal SAH and a hospital length of stay of at least
3 days. Patients were excluded if their SAHwas due to trauma, if they
had inadequate medication administration records or incomplete
medical records, or if they presented with Hunt and Hess Grade V
SAH [7]. Grade V SAH patients were excluded due to the relative lack
of qualitative assessment of pain in these patients by the nursing
staff. Local institutional review board approval was obtained via
expedited review.
The primary outcome of the study was to evaluate the pain scores
associated with headache in patients within seven days of a SAH.
Secondary outcomes included a description of the use of analgesic
medications for the treatment of headache within the same time
period and the incidence of early vasospasm as it related to headache.
Data points that were collected included patient demographic data,
SAH characteristics (location, severity, method of embolization), total
analgesic dose per day for the ﬁrst seven days after ictus, dailyTable 1
Patient demographics.
Total (n=108)
Age (years) Mean(S.D) 52.3 (13.1)
Gender (n, % female) 68 (63.1%)
Weight (kg) Mean (S.D.) 81.7 (27)
History of tobacco use (n, %) 69 (63.6%)
Presenting Hunt & Hess score
Median (IQR)
2 (0)
Method of aneurysm embolization
Clipping 12 (11.1%)
Coiling 59 (54.6%)
None 37 (34.3%)
N, (%)
ICU length of stay (days) Mean (S.D.) 4.5 (7)
Hospital length of stay (days) Mean (S.D.) 9 (7)
Discharge disposition
Home 87 (80.6%)
Acute rehabilitation 15 (13.9%)
Long-term care facility 3 (2.8%)
Deceased 3 (2.8%)maximum pain scores (standardized score of one to ten), presence of
clinical vasospasm as dictated in daily physician progress notes,
cerebral blood ﬂow velocity measurements (via transcranial Dopplers
(TCDs)), and pertinent laboratory values.
Management of SAH patients in our institution is consistent with
published guidelines [8]. Speciﬁcally, blood pressure is rigorously
controlled upon admission (typical goal is systolic blood pressure
b 140–150 mmHg). Nimodipine 60 mg PO/per tube q4 h and
atorvastatin 80 mg PO/per tube daily are initiated on hospital day 1.
Digital subtraction angiography is performed as soon as is feasible to
describe the location and morphology of the aneurysm and aneu-
rysms are secured via endovascular coiling or surgical clipping as soon
as possible. After the aneurysm is secured, patients are kept euvolemic
and the blood pressure is typically permitted to rise to no greater than
a systolic blood pressure of 180 mmHg. TCDs are evaluated daily.
Sedating medications are avoided whenever possible. SAH patients
typically reside in the intensive care unit for frequent and, often
invasive, monitoring. Pain scores (on a 10-point analog scale) are
monitored routinely. Magnesium concentrations are routinely mon-
itored and serum concentrations are generally targeted to be in the
normal range (2–2.8 mg/dl). Vasospasm was deﬁned as clinical
symptoms or radiographic ﬁndings as judged by the attending
physician and documented in the medical record.
For the primary outcome, a univariate analysis was used to
determine if there is an association between the presence of
vasospasm and the amount of Fioricet® in tablets per day adminis-
tered. A two sample t-test was used for interval/ratio data and the Chi
squared test was used for categorical variables. Multivariate logistic
regression was used to model the odds of vasospasm among patients
with Fioricet® exposure, adjusting for age and SAH severity (as
measured by Hunt and Hess Score) [9]. We dichotomized Hunt and
Hess Score into groups of 1–2 and 3–4 for the purposes of the
multivariate analysis [10,11]. Data analysis was conducted using SAS,
v.9.3; an alpha level of 0.05 was used throughout.
Results
The UHC database identiﬁed 244 patients whowere admitted with
a SAH within the designated time period. Of those patients, 136
patients were excluded. The top reasons for exclusion included a
length of hospitalization less than 3 days or Hunt and Hess Grade V
SAH on presentation. Of the 108 patients who were included within
the analysis, 34 patients (31.5%) experienced vasospasm withinVasospasm (n=34) No vasospasm (n=74) P-value
48.7 (11.8) 54.6 (12.6) 0.02
25 (73.5%) 43 (58.1%) 0.123
80.9 (21.1) 82.9 (29.4) 0.726
23 (67.6%) 45 (61.6%) 0.494
2 (1) 2 (0) 0.21
5 (14.7%) 7 (9.5%)
20 (58.8%) 39 (52.7%)
9 (26.5%) 28 (37.8%)
8 (9) 4 (5) 0.002
13.5 (7.75) 9 (5) 0.004
24 (70.6%) 63 (85.1%)
8 (23.5%) 7 (9.5%)
0 (0%) 3 (4.1%)
2 (5.9%) 1 (1.4%)
Table 2
Analgesics for SAH headachea.
Total
(n=108)
Patients with
vasospasm who
received speciﬁc
therapy (n=34)
Patients with no
vasospasm who
received speciﬁc
therapy (n=74)
P-value
Fioricet 94 (87%) 33 (97.1%) 61 (82.4%) 0.036
Acetaminophen 54 (50%) 21 (61.8%) 33 (44.6%) 0.097
Ibuprofen 10 (9.3%) 2 (5.9%) 8 (10.8%) 0.411
Ketorolac 18 (16.7%) 10 (29.4%) 8 (10.8%) 0.016
Total morphine
equivalentsb
87 (80.5%) 26 (76.5%) 61 (82.4%) 0.467
Dexamethasone 26 (24.1%) 10 (29.4%) 16 (21.6%) 0.379
a All data for medications include N (%) of patients who received speciﬁc agent.
b Includes equipotent doses of oral opioids (hydrocodone, oxycodone, and codeine)
and IV morphine.
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patient characteristics and the treatment of their SAH. Generally, the
population was comparable to previously described SAH patients
[12,13]. Most patients were female (63.1%), with a mean age of
52.8 years, and a high prevalence of smoking (63.6%). Many of the
patients underwent endovascular coiling for their aneurysm and had a
prolonged hospital stay. The median Hunt and Hess score for patients
included was 2 (range 1–4).
Overall, the SAH patients exhibited a consistent increase in their
maximum daily pain score, rising from amedian of 5 on hospital day 1
to 8 on hospital day 7 (Fig. 1). This increase appeared independent of
the type or amount of pain medication given. Patients with early
vasospasm had a higher overall median daily pain score than did
patients without vasospasm (early vasospasm pain score 8 vs. no
vasospasm pain score 6, p = 0.0002). These data suggest that the
headache associated with aneurysmal SAH is severe and increases in
severity as the patient progresses through the putative vasospasm
window. In addition, the presence of early vasospasm may be
signiﬁcantly associated with the worsening of headache during this
time period. Only one patient (1/14) who experienced early
vasospasm had a mild headache (maximum pain score ≤ 4), whereas
35.5% (27/76) of patients with severe headache (maximum pain score
≥ 8) had early vasospasm(p=0.035).Mean TCDvalues also increased
similarly to pain score during this period (Fig. 2). Overall, mean TCD
values were not signiﬁcantly different (either mean measurements or
Lindegaard ratio) in patients with mild vs severe headache.
The primary analgesicmedication given to patients in this cohort of
patients was Fioricet (Table 2). Nearly every patient in this cohort
(87%) received at least one dose of Fioricet during the ﬁrst 7 days of
admission. The mean number of tablets of Fioricet given per day
increased from 1.6 (SD 2.1) on hospital day 1 to a peak of 5.9 (SD 4.1)
on hospital day 5. While some patients required no analgesic
medications on a given day, over 32% of the patients required a
mean of N 5 Fioricet tablets per day (including 47% of the patients who
exhibited early vasospasm). Overall, patients with no vasospasm
received comparatively less (4.3 tablets) Fioricet per day compared to
patients with early vasospasm, though the difference was not
statistically signiﬁcant (5.5 tablets per day, p = 0.055). Patients with
early vasospasm also tended to receive opioid agents slightly more
than patients without vasospasm, although this was not statistically
signiﬁcant (8.2 mg morphine equivalents vs 5.4 mg morphine
equivalents, p = 0.056). Other analgesics were used for headache
pain including morphine, oral opioid agents, and NSAIDs such as
ibuprofen and ketorolac (Table 2). Patients with early vasospasm
tended to require more pain medications, with Fioricet and ketorolac0
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Fig. 2. Daily headache pain scores in patients with and without vasospasm.being used signiﬁcantly more in the early vasospasm group. Most of
these agents aside from Fioricet and acetaminophen were used
sparingly and none of the agents were associated with an improve-
ment in pain score overall. As the number of doses of Fioricet or other
analgesics increased, the pain scores also increased, suggesting that
the headache is typically treatment-refractory and/or the medications
being used to treat the headache are largely ineffective.
The serum magnesium concentration was also examined for each
patient. Nearly all patients (94%) had at least one magnesium
concentration obtained during the ﬁrst 7 days of their hospital stay
(though most patients had magnesium monitored daily). The mean
magnesium concentration was 2 mg/dl (SD 0.36) and was not
different between patients who had early vasospasm vs no vaso-
spasm.Magnesium concentrations N2 mg/dl were not associatedwith
lower pain scores or improvements in pain scores.
A multivariate analysis was also performed in order to determine
any relationship with vasospasm and patient factors (Table 3). In the
univariate analysis, age, amount of Fioricet use, and TCD values were
positively associated with the occurrence of early clinical vasospasm.
However, the results of the multivariate analysis did not demonstrate
a signiﬁcant associationwith age, Fioricet use or TCD values with early
clinical vasospasm.
Discussion
This study of headache in the ﬁrst 7 days after aneurysmal SAH
demonstrates that headache is common, even days after the sentinel
hemorrhage. Patients who develop cerebral vasospasm early after
SAH have a signiﬁcantly higher pain score related to their headache
than do patients without vasospasm. Additionally, patients who
complained of a severe headache (deﬁned as a pain score ≥8/10)
more frequently developed early vasospasm than did patients who
complained of a mild headache (deﬁned as a pain score ≤4/10).
Unfortunately, a wide variety of agents was used in our cohort with
limited success. This is the ﬁrst study to speciﬁcally describe the
severity of headache after aneurysmal SAH.Table 3
Multivariate logistic regression predicting the outcome of clinical vasospasm.
Variable Parameter Estimate Odds ratio 95% CI for OR P-value
Age −0.034 0.97 0.93–1.00 0.08
Hunt and Hess Scorea −0.340 0.51 0.19–1.37 0.2
Average Fioricet Doseb 0.096 1.10 0.96–1.27 0.2
a Hunt and Hess Score was dichotomized as 1+2 vs 3+4. Hunt and Hess Score of
3+4 was used as reference in multivariate logistic regression.
b Mean dose for Fioricet was expressed as tablets per day.
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is signiﬁcant and that it increases in intensity during the ﬁrst 7 days
after ictus. While the mechanism of headache after SAH is not well
described, it is plausible that many of the factors that contribute to the
development of vasospasm may also lead to headache. Certainly, the
chemical irritation of blood on the meninges and in the subarachnoid
space is thought to cause pain. In addition, inﬁltration of immune
cells, immune activation, and inﬂammatory cytokines likely also
contribute to the pain associated with headache [14]. It may also be
possible that alterations in brain perfusion associated with vasospasm
may factor in the intensity of the headache. Very little data are
available to directly corroborate these mechanisms, so much research
in this area is needed before clinicians have a better understanding of
the disease process.
The use of Fioricet as the primary analgesic in this cohort did not
appear to be effective. Despite an increase in daily usage throughout
most of the ﬁrst 7 days after ictus, the median daily pain scores
continued to rise. Concerns about the safety of using this combination
agent were not entirely disproven. A univariate analysis of factors
associated with vasospasm suggested that daily Fioricet dose was
associated with the development of vasospasm. However, the multi-
variate analysis, when correcting for severity of SAH and age, did not
show a signiﬁcant association. It is difﬁcult to discern whether an
increased dose of Fioricet promoted the development of vasospasm or if
increasing vasospasm was associated with worsening headache (and
hence the need for more analgesia). The pharmacology of caffeine and
the impact on cerebral vasoconstriction still merit further study to
ensure that clinicians are not administering a deleterious agent in this
clinical context. In addition, the subtle effects of a long-acting
barbiturate like butalbital are difﬁcult to evaluate in a retrospective
study design. It is unknownwhether receipt of this agent had an impact
on patient wakefulness or neurologic exam. Certainly, avoiding CNS
depressants in patients where small, insidious changes in neurologic
exam may herald signiﬁcant morbidity continues to be advisable. We
also did not detect a signiﬁcant occurrence of acetaminophen over-
dosing, although it is generally our practice to be vigilant about the
amount of acetaminophen available to be given on a daily basis in these
patients. Of the 729 patient days evaluated, there were 9 instances
(1.2%) where a patient received 4 g of acetaminophen or more
(maximum in one day was 4575 mg). No liver toxicity was noted in
any of the patients studied. Clearly Fioricet, in addition to others, is not a
panacea for the treatment of peri-SAH headaches.
There are several limitations to this study and the interpretation of
the data. First, as a retrospective study, we are missing many of the
qualitative aspects of the pain score and the patient experience after
SAH. In the future, prospective studies in this area should includemore
qualitative assessment of the patient’s pain and comfort. Second,
analgesics were not used in a protocolized manner. While this is quite
reﬂective of a ‘real-life’ scenario, it alsomakes evaluationof the efﬁcacy
of these agents difﬁcult. It is quite possible that a systematicmethod of
treating headache in these patients (escalating doses of medications,
strategic combinations of agents which might synergize in effect, etc.)
may bemore beneﬁcial than a variable, inconsistent practice. Third, for
patients who had limited consciousness, there was not an established
nursing protocol for headache assessment and treatment. Intensive
care nurses often use physiological and behavioral cues to evaluate
pain in these cases (tachycardia, grimacing, agitation, etc.), but this is
challenging to quantify on a 10-point analog scale. Therefore, we are
limited in evaluating these data in the context of severe SAH patients
or those with declining GCS. Fourth, we did not include the
development of hydrocephalus in our analysis of headache pain.
However,we typically employ CSF diversionwith a ventriculostomy to
attenuate hydrocephalus in these clinical situations, so we do not
believe this factored greatly into our results. Finally, acceptable painlevels are different for each unique patient (and often different for a
given patient on different days). We did not evaluate the pain score in
light of the patient’s stated acceptable pain score, so it is possible that
some patients had a relatively high pain score, but did not consider it
clinically signiﬁcant. However, the incremental trend we observed in
pain score suggests that pain did worsen considerably in the
cohort overall.
Conclusions
We evaluated headache pain scores in patients within 7 days of
their aneurysmal SAH. Overall, pain scores increase on a daily basis
after SAH, rising fromamedianof 5 onday 1 to 8 onday 5. Patientswho
developed cerebral vasospasm appeared to have a more severe
headache than those patientswho did not develop vasospasm. Fioricet
was the primary analgesic administered for headache in this cohort.
Our data suggest that this agent was largely ineffective in treating
headache in these patients. Furthermore, a univariate analysis
suggested that Fioricet may be associated with early vasospasm,
although this was not corroborated by the multivariate analysis
correcting for SAH severity and age. This is the ﬁrst descriptive report
of the course and severity of headache after aneurysmal SAH. It seems
clear that this is a signiﬁcant problem for patients after ictus and that
our current treatment strategies are not effective at this point.
Prospective evaluation of treatment strategies aimed at providing
adequate analgesia while not confounding neurologic exam or
contributing to other morbidity after SAH is needed.
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